At the 76th annual meeting of the American Academy of Dermatology, Johnson &...
Fast Trak Services: A collaborative Project to Accelerate Downstream Biosimilar Process Development
Biosimilars represent an innovative solution to benefit both patients and healthcare systems by reducing the burden of rising treatment costs.
AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?
At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder analysis of their interleukin 23 subunit alpha (IL-23A) inhibitor Tremfya (guselkumab) compared with Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Eli Lilly’s IL-17A inhibitor Taltz (ixekizumab) for the treatment of moderate to severe plaque psoriasis (PsO).
Small pharma steals the spotlight in 2017 antibiotics space
In November 2017, Melinta Therapeutics acquired The Medicine Company’s infectious diseases business unit as part of a $270M agreement, capping off an active 12 months for small-cap pharmaceutical companies in the antibiotics R&D space.
What defines an over-the-counter drug?
India has decided to rethink which medicines can and can’t be sold without prescriptions. These measures will finally create a definition for over the counter (OTC) drugs and possibly curb the sale of some dangerous medicines. So what separates OTC drugs from prescription-only and why is this categorisation so important?
MESM: Expert Medical Equipment Supplier
When every detail matters and when every second counts, expert support makes the difference. MESM has supplied equipment to nearly 2,000 global trials and hit the SIV date 99.9% of the time.
ExtaviPro®30G is the Solution to Low Adherence in MS Treatment
Multiple sclerosis (MS) is a chronic debilitating inflammatory disease of the central nervous system, which affects 2.5 million people worldwide.
Oxford BioMedica and Bioverativ enter $100m gene therapy deal
UK-based Oxford BioMedica has signed a new collaboration and licence agreement with Bioverativ for the development and manufacture of lentiviral vectors to treat haemophilia.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.